CDK1

CDK1
Name	Cyclin-dependent kinase 1
Organism	Homo sapiens
Uniprot	P06493

CDK1 is a highly conserved serine/threonine protein kinase that serves as a master regulator of eukaryotic cell cycle progression, particularly the transitions into mitosis. It integrates signals from checkpoint pathways and growth factor cascades to coordinate DNA replication, chromosome segregation, and cytokinesis. Research on CDK1 intersects with studies by laboratories associated with the Nobel Prize in Physiology or Medicine, work at the Max Planck Society, collaborations involving the Howard Hughes Medical Institute, and translational projects at institutions like Memorial Sloan Kettering Cancer Center.

Function

CDK1 functions as the catalytic subunit of mitotic holoenzymes that phosphorylate substrates required for mitotic entry, spindle assembly, and mitotic exit, as characterized in experiments originating from the Mendelian inheritance era and refined through methods developed at the Sanger Institute and the Cold Spring Harbor Laboratory. It drives G2/M transition processes studied alongside regulatory factors in models from the Saccharomyces cerevisiae genetic system to mammalian systems used at the National Institutes of Health and the European Molecular Biology Laboratory. CDK1-dependent phosphorylation events are central to pathways examined in the context of the Nobel Prize in Physiology or Medicine 2001 discoveries and in signaling networks explored in papers from the Cell Press and Nature Publishing Group.

Regulation and Activation

Activation of the kinase requires association with regulatory cyclins, removal of inhibitory phosphorylations by phosphatases such as those characterized at the Pasteur Institute and the Weizmann Institute of Science, and localization changes described in studies from the University of Cambridge and Massachusetts Institute of Technology. Key regulatory inputs include the ATR- and ATM-mediated checkpoint signaling pathways elucidated in work connected to the Howard Hughes Medical Institute and clinical studies at the Dana-Farber Cancer Institute. CDK1 activity is modulated by ubiquitin-mediated proteolysis involving E3 ligases studied within the European Research Council frameworks and by kinase cascades investigated at the Institute of Cancer Research.

Structure and Mechanism

The kinase domain of CDK1 adopts the canonical bilobed fold seen in structures solved by groups at the European Molecular Biology Laboratory and published in journals associated with the American Association for the Advancement of Science. Structural studies using X-ray crystallography and cryo-EM performed at the Max Planck Institute for Biophysical Chemistry revealed ATP-binding motifs and activation segment conformations that control catalysis, analogous to mechanisms described in structural papers from the Rockefeller University and the University of Oxford. Mechanistic insights draw on enzymology traditions from laboratories allied with the Royal Society and computational modeling efforts at the Allen Institute for AI.

Role in Cell Cycle and Mitosis

CDK1 orchestrates mitotic programs first inferred from classical cytology taught at institutions such as Harvard University and formalized in textbooks used at the University of California, Berkeley. Its essential role in driving prophase, prometaphase, and metaphase is supported by genetic and biochemical studies from groups at the Cold Spring Harbor Laboratory and the Johns Hopkins University School of Medicine. CDK1 activity is coordinated with centrosome dynamics studied at the European Molecular Biology Laboratory and chromosome condensation pathways investigated in collaborations with the Ludwig Institute for Cancer Research.

Interactions and Substrates

CDK1 forms complexes with cyclins studied in pioneering work at the State University of New York and phosphorylates numerous substrates including condensins, cohesins, motor proteins, and nucleoporins, with mechanistic follow-up by teams at the Max Delbrück Center and the University of Geneva. Protein–protein interaction maps incorporating data from consortia like the Human Genome Project and projects at the Broad Institute catalog CDK1 substrates and regulatory partners identified in mass spectrometry studies at the Proteomics Standards Initiative.

Clinical Significance and Disease Associations

Dysregulation of CDK1 activity contributes to oncogenesis and chromosomal instability observed in clinical cohorts assembled by centers such as Memorial Sloan Kettering Cancer Center and the Mayo Clinic. CDK1 pathway alterations have been implicated in tumor types profiled by the Cancer Genome Atlas and in therapeutic studies conducted at the National Cancer Institute. Small-molecule inhibitors targeting CDK complexes have been developed in industry collaborations involving Pfizer, Novartis, and academic spinouts from the University of Pennsylvania and are under evaluation in trials overseen by agencies like the Food and Drug Administration.

Experimental Tools and Measurement Methods

Investigation of CDK1 employs genetic tools from repositories like the Addgene plasmid bank and model organisms maintained by the Jackson Laboratory, biochemical assays refined at the Cold Spring Harbor Laboratory, and live-cell imaging platforms developed at the European Molecular Biology Laboratory. Quantitative proteomics, phospho-specific antibodies produced by companies associated with the Biotechnology Industry Organization, and high-throughput screening carried out at facilities such as the Wellcome Trust Sanger Institute enable measurement of CDK1 activity and substrate phosphorylation dynamics. CRISPR-based perturbations designed following protocols from the Broad Institute and computational analyses using pipelines from the European Bioinformatics Institute are routine in current CDK1 research.

Category:Cell cycle proteins Category:Human proteins